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TREATMENT COSTS ATTRIBUTABLE TO OVERWEIGHT/OBESE
IN PATIENTS WITH DIABETES MELLITUS IN THE U.S.ADULT
POPULATION
Kim CM1, Choi IS2, Huang J2, Suh DC2, Barone JA2
1Catholic University, Seoul, Suhcho-gu, South Korea,
2Rutgers University, Piscataway, NJ, USA
OBJECTIVES: To estimate treatment costs attributable to over-
weight or obesity in diabetic patients. METHODS: Data from
23,825 adults in the 2004 Medical Expenditure Panel Survey
(MEPS), a nationally representative sample of the U.S. non-insti-
tutionalized population, were examined for this cross-sectional
analysis. Diabetic patients were identiﬁed if they reported having
diabetes in the medical conditions ﬁle of MEPS. Based on their
BMI, patients were further classiﬁed as normal (body mass index
(BMI 18.5 to <25), overweight (BMI 25 to <30), or obese (BMI
≥ 30). Treatment costs associated with diabetes mellitus included
costs for treating kidney and heart disease, stroke, eye, skin, and
foot complications, and neuropathy. The costs for overweight or
obese patients were predicted from estimated parameters in
patients with normal weight using a generalized linear model
with log link function, with adjustment for patients’ demo-
graphic characteristics, BMI, services used, and co-morbidities.
Attributable costs were estimated by the difference between pre-
dicted costs and observed costs. All costs were converted to 2005
U.S. dollars using appropriate price indices. Data were analyzed
using SAS and SUDAAN statistical software to adjust for the
complex sample design. RESULTS: The age-adjusted prevalence
of diabetes in the U.S. population was 6.26% (15.3 million
people). More than 80% of diabetic patients were overweight
(30.4%) or obese (51.4%). Among obese patients, the medical
costs associated with diabetes were higher in women ($6263)
than men ($4505), as well as in white ($6209) than black
($4819) or Hispanic ($2421) patients. Overall, compared to
patients with normal weight, predicted costs attributable to over-
weight were $709 (95% CI:$237–$1181) and obesity, $2301
(95% CI:$748–$3854). CONCLUSION: Overweight and
obesity were prevalent in diabetic patients that signiﬁcantly
increased economic burden. Patient education to emphasize the
importance of weight control is strongly recommended to reduce
treatment costs attributable to diabetic complications.
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EMERGENCY ROOM CARE FOR DIABETES MELLITUS IN THE
UNITED STATES: HOW MUCH DOES IT COST?
Addo-Atuah J,Waters T,White-Means S, Gourley D
University of Tennessee Health Science Center, Memphis,TN, USA
OBJECTIVES: The objectives of this study were (1) To provide
a population-based estimate of the cost of emergency room care
for the US population with diabetes in 2006 dollars and; (2) To
examine if there are any differences in ER costs for the study
population by age, gender, race, ethnicity, marital status, insur-
ance status, educational level, family income, census region,
locality, body mass index, and comorbidities/complications
METHODS: This was a cross-sectional retrospective study of the
cost of emergency room care for individuals with diabetes. The
data source for the study was the 2003 MEPS Household Com-
ponent Full Year Consolidated File (MEPS HC-079, 2003).
People reporting diabetes in the MEPS data ﬁle were identiﬁed
by the ICD9-CM code 250 (diabetes) and the relevant ICD9-CM
codes were used to further identify those individuals reporting
both diabetes and any of the associated comorbidities/complica-
tions after merging the data by the person identiﬁcation number
DUPERSID. The total cost of ER care for the study population
was computed by summing the facility and provider costs for the
year and then adjusted to 2006 dollars. Differences in the mean
ER cost for diabetes by each of the demographic and clinical
variables were tested for signiﬁcance using two sample t-tests.
All computations and analyses incorporated the MEPS sampling
weights to obtain estimates for the noninstitutionalized US civil-
ian population with diabetes in 2003. RESULTS: The total cost
of ER care for diabetes in 2003 was $3.1 billion adjusted to $3.4
billion in 2006 dollars. The difference in the mean ER cost was
signiﬁcant only by gender and educational level. CONCLU-
SION: ER care for diabetes cost $3.4 billion in 2006. Appro-
priate educational interventions might be needed for people with
diabetes so they can better cooperate with their providers in their
disease management so as to reduce ER use and costs.
PDB17
DETERMINATION OF HEALTH CARE COSTS INCURRED BY
SWEDISH PATIENTS WITH TYPE 2 DIABETES
Ringborg A1, Stålhammar J2, Martinell M2,Yin D3, Lindgren P1
1European Health Economics, Stockholm, SE, Sweden, 2Uppsala
University, Uppsala, Sweden, 3Merck & Co., Inc, Whitehouse Station,
NJ, USA
OBJECTIVES: The objective of the present study was to esti-
mate annual costs of care incurred by Swedish patients with type
2 diabetes between 2000 and 2004 and to determine the drivers
of costs using data from the RECAP-DM study, which included
medical records on 11,856 patients with type 2 diabetes 
retrospectively identiﬁed in computerised registers at 26 primary
care centres in Uppsala county (°Ö300,000 inhabitants).
METHODS: Costs of outpatient care, drugs and devices were
estimated by assigning unit costs from published sources to 
care-giver contacts and prescriptions recorded in computerised
primary care records. Costs of inpatient care were estimated by
classifying hospitalisations of study patients into diagnosis-
related groups (DRGs) according to the Nord-DRG classiﬁcation
system and assigning average costs per DRG. Costs of dialysis
were estimated using data from the Swedish Register for Active
Care of Renal Failure. Drivers of costs were analysed through
multiple regression analysis. RESULTS: The average annual cost
of care over the studied years was $2658 per patient (n = 7269
on average). Costs of inpatient care accounted for an average
59% of total costs. Results of the regression analysis indicated
that the main driver of costs was the presence of complications.
Undergoing treatment for renal failure in a given year was asso-
ciated with a $70,682 increase in total costs of care during the
year. Experiencing a major cardiovascular event (acute MI,
stroke, PCI or CABG) in a given year was associated with a
$15,094 increase in total costs of care during the year. CON-
CLUSION: Diabetes continues to impose a heavy economic
burden on society. Cost estimates from this population-based
sample of Swedish type 2 diabetics may serve as reference values
for a Swedish setting and provide additional information on the
composition of costs.
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THE RELATIVE COST EFFECTIVENESS OF INSULIN
GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA
IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
McEwan P1, Mehin N2,Tetlow AP3, Sharplin P3
1Cardiff University, Cardiff, South Glamorgan, UK, 2sanoﬁ-aventis, Paris,
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OBJECTIVES: The purpose of this study was to evaluate the cost
effectiveness (cost utility) of insulin glargine in the UK for people
with Type 2 diabetes mellitus (T2DM) using observational data
in patients continuing on NPH versus those switching from NPH
to insulin glargine. METHODS: A discrete event simulation was
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developed with a time horizon of 40 years. Transition probabil-
ities for macrovascular and microvascular complications were
drawn from the UKPDS 68 Outcomes equations. Direct costs
and quality of life (EQ5D) were derived from published sources
and the HODaR database respectively; costs and beneﬁts were
discounted annually at 3.5%. This model was adapted for Type
2 patients switched from NPH to glargine identiﬁed from 
the THIN database, a UK primary care database including
2,335,667 active patients recorded over 15 years from 211 prac-
tices. Analysis was conducted on a total of 181 patients with
data for the 12 month period prior to and post switch to
glargine; the primary outcome measure was Hba1c change.
RESULTS: The median age at switch from NPH was 71 with
mean duration of T2DM of 9.2 years. Baseline HbA1c was
8.79% and patients switching to glargine showed a signiﬁcant
reduction in HbA1c of 0.67%(p = 0.00384) between switch to
glargine and 12 months post glargine initiation. Incorporating
this into a simulated cohort of 10,000 patients followed over a
40 year time horizon translated into 150 fewer cardiovascular
events. Average cost per patient was ≤4338 and ≤3370 for
glargine and NPH respectively, providing discounted quality
adjusted life years (QALYs) of 4.96 and 4.86 respectively; result-
ing in a discounted incremental cost effectiveness ratio (ICER)
of ≤9200 per QALY. CONCLUSION: Based on UK real life
observational data, switching to basal insulin in type 2 DM
patients from NPH to glargine is cost-effective; with a corre-
sponding ICER within accepted thresholds for cost-effective
treatments.
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GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA
IN TYPE 1 DIABETES MELLITUS
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OBJECTIVES: The purpose of this study was to evaluate the cost
effectiveness (cost utility) of insulin glargine in the UK for people
with Type 1 diabetes mellitus (T1DM) using observational data
in patients continuing on NPH versus those switching from NPH
to insulin glargine. METHODS: A discrete event simulation
model was developed with a time horizon of 40 years. Transi-
tion probabilities for progression to microvascular complications
were derived from the DCCT (Diabetes Control and Complica-
tions Trial) with cardiovascular events modelled via the Fram-
ingham equations. Direct costs and quality of life (EQ5D) were
derived from published sources and the HODaR database
respectively; costs and beneﬁts were discounted annually at
3.5%. The model was adapted to the proﬁle of T1DM patients
switched from NPH to glargine identiﬁed via the THIN database
(The Health Improvement Network), a UK primary care data-
base including 2,335,667 active patients recorded over 15 years.
Analysis was conducted on a total of 466 patients with data for
the 12 month period prior to, and post switch; the primary
outcome measure of Hba1c change. RESULTS: The median age
of patients switched from NPH to glargine was 33 years with
mean duration of T1DM of 8.1 years. Baseline HbA1c was
8.71% and patients switching to glargine showed a reduction in
HbA1c of 0.27% between switch and 12-months post initiation.
Over 40 years, in a simulated cohort of 10,000 there were 523
fewer fatal microvascular complications and, on average, 1 less
microvascular complication per patient in those receiving
glargine compared to NPH. The discounted incremental cost
effectiveness ratio (ICER) was £6527 per quality adjusted life
year (QALY) gained. CONCLUSION: Based on UK real life
observational data, switching to basal insulin in type 1 DM
patients from NPH to glargine is cost-effective; with a corre-
sponding ICER well within accepted thresholds for cost-effective
treatments.
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COMPARISON OF ROSIGLITAZONE VERSUS PIOGLITAZONE
INTRODUCTION AND ASSOCIATED HEALTH CARE
UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES
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OBJECTIVES: Outcomes in type 2 diabetes patients can differ
based on the antidiabetic medication that is used. Thiazolidine-
diones (TZD) are a newer class of agents used for type 2 dia-
betes treatment. Previously, no study has compared health care
utilization associated with the two TZDs on the market. The
objective of this study was to compare health care utilization
between two TZDs used by Medicaid-enrolled patients with type
2 diabetes. METHODS: This was a retrospective data analysis
comparing cohorts of patients with type 2 diabetes starting a new
antidiabetic medication for hospitalizations, emergency room
visits, outpatient visits, and health care costs. A total of 660
patients starting rosiglitazone between July 1, 2001 to June, 30,
2002 were compared to 1045 patients staring pioglitazone
during the same period. The patients were followed up for 30
months to examine the difference in health care utilization over
time. Multivariate regression techniques were employed for com-
parisons between different antidiabetic therapies. RESULTS:
Multivariate analysis showed that rosiglitazone group was asso-
ciated with almost 12% decrease in the mean number of hospi-
talizations, and 10 % decrease in the mean number of emergency
room visits, and a 7.3% decrease in total health care costs 
as compared to the pioglitazone group (all p < 0.05). CON-
CLUSION: Introduction of rosiglitazone was associated with
decreased number of hospitalizations, emergency room visits,
and total health care costs compared to pioglitazone. The uti-
lization of oral antidiabetic agents, with documented clinical and
economic beneﬁts, should continue to be advocated to reduce
avoidable medical care utilization, and improve patient out-
comes in this population.
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PRICE AND UTILIZATION OF ORAL ANTI-DIABETIC
MEDICATIONS FROM 1991 TO 2005 IN U.S. MEDICAID
PROGRAMS
Li X, Doherty M, Kelton CM, Jing Y, Guo JJ
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: Diabetes is the sixth leading cause of death in the
United States, and its prevalence has been increasing. The annual
cost of this illness to society reached close to $100 billion in
1999. The objective of this study is to analyze the trends of price
and utilization of oral anti-diabetic medications in U.S. state
Medicaid programs. METHODS: Oral anti-diabetic drugs
include ﬁrst- and second-generation sulfonylureas, α-glucosidase
inhibitors, biguanides, thiazolidinediones, meglitinides, and
combination drugs. Data were taken from the national Medic-
aid pharmacy claims databases for 1991 to 2005, provided by
the Centers for Medicare & Medicaid Services. Descriptive time-
series analysis was used to assess quarterly prescription numbers,
amount of reimbursement, and cost per prescription. RESULTS:
